Ophthalmic Formulations Of Cetirizine And Methods Of Use
AssigneeAciex Therapeutics, Inc.
InventorsMark B. Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice
Life of this patent
Estimating the term…
Abstract
The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis rhinitis, and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Claims27
A topical ophthalmic formulation comprising about 0.1% cetirizine (w/v) or a pharmaceutically acceptable salt thereof and about 0.005% fluticasone (w/v).
A topical ophthalmic formulation comprising 0.1% cetirizine (w/v), 0.005% fluticasone (w/v), 1% Polyethylene Glycol 400, NF, 0.2% Dibasic Sodium Phosphate, Anhydrous, USP, 0.25% Hypromellose, USP, 0.1% Polysorbate 80, NF, 1.8% Glycerin, USP, 0.025% Edetate Disodium, USP, 0.01% Benzalkonium Chloride, NF.
Dependencies are inferred from the claim text.